A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage 3B/4 nonsquamous non-small cell lung cancer (NSCLC): Analysis of safety and activity of the FALCON trial.
E. B. Garon
Consultant or Advisory Role - Oxigene (U)
Research Funding - Oxigene
F. F. Kabbinavar
No relevant relationships to disclose
J. A. Neidhart
Research Funding - Oxigene
J. D. Neidhart
Research Funding - Oxigene
N. Y. Gabrail
No relevant relationships to disclose
M. R. Oliveira
Consultant or Advisory Role - Oxigene
S. Lu
Employment or Leadership Position - Oxigene
J. Balkissoon
Employment or Leadership Position - Oxigene
Stock Ownership - Oxigene